Document Detail


Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man.
MedLine Citation:
PMID:  17460420     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Gemcitabine, a pyrimidine analogue, is a cell cycle-specific antineoplastic agent that is structurally related to cytarabine. Major side effects of the treatment with gemcitabine are hepatic dysfunction, myelosuppression, renal impairment and pulmonary toxicity. Development of atrial fibrillation (AF) during gemcitabine treatment is very rare and was reported in only 2 case reports in the literature. CASE REPORT: We report the case of a 65-year-old man who developed AF under gemcitabine therapy for non-small cell lung cancer (stage IIIB). In this patient, AF was intrinsically associated with chemotherapy administration which triggered arrhythmia. CONCLUSION: Although AF caused by gemcitabine appears to be rare, patients at risk of developing atrial fibrillation should be closely monitored for this complication.
Authors:
Yusuf Tavil; Ugur Arslan; Kaan Okyay; Nihat Sen; Bülent Boyaci
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2007-04-24
Journal Detail:
Title:  Onkologie     Volume:  30     ISSN:  0378-584X     ISO Abbreviation:  Onkologie     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-26     Completed Date:  2007-07-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7808556     Medline TA:  Onkologie     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  253-5     Citation Subset:  IM    
Affiliation:
Gazi University Medical School, Department of Cardiology, Ankara, Turkey. yusuftavil@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antimetabolites, Antineoplastic / administration & dosage,  adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects*,  therapeutic use
Atrial Fibrillation / chemically induced*,  diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Cisplatin / administration & dosage,  adverse effects
Deoxycytidine / adverse effects,  analogs & derivatives*,  therapeutic use
Electrocardiography / drug effects
Humans
Infusions, Intravenous
Lung Neoplasms / drug therapy*,  pathology
Male
Neoplasm Staging
Risk Factors
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 103882-84-4/gemcitabine; 15663-27-1/Cisplatin; 951-77-9/Deoxycytidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Penile metastasis from a T1b prostate carcinoma.
Next Document:  Multiple littoral cell angioma of the spleen: a case report and review of the literature.